Opus Genetics, Inc. (IRD) bonds

IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30460% above fair value

$3.98−0.08 (-1.97%)

Close on Nov 13, 2026Market cap $331.12MP/E –Yield –

Debt

Borrowings on the balance sheet, Sep 30, 2026

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

As tagged in Opus Genetics's 10-Q for the period ended Apr 2, 2026

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.

Revolving credit lines and other committed borrowing capacity

Facility	Size	Available	Expires
Convertible Senior Notes Due 2033	$155.00M	$50.00M	2033

Parsed from the XBRL in Opus Genetics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-4 reverse split on Nov 6, 2020
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IRD.

Revenue growth-45.9% · median -93.5%

Operating margin-777.7% · median -2652.8%

Net margin-1726.7% · median -2606.4%

Advertisement
300 × 250

See a number that looks wrong?